Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Rating of “Strong Buy” by Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has received an average recommendation of “Strong Buy” from the eight research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and six have assigned a strong buy rating to the company.

A number of analysts have weighed in on the company. Zacks Research upgraded Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 15th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Finally, BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th.

Zealand Pharma A/S Trading Down 0.1%

Shares of OTCMKTS:ZLDPF opened at $77.00 on Tuesday. Zealand Pharma A/S has a 52 week low of $49.98 and a 52 week high of $110.00. The company’s 50 day moving average is $76.67 and its two-hundred day moving average is $68.33. The company has a market cap of $5.47 billion, a PE ratio of 5.54 and a beta of 0.72. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.21. The business had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. Equities analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.